Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Pressure BioSciences's 3-Year RORE % for the quarter that ended in Jun. 2024 was 0.00%.
The industry rank for Pressure BioSciences's 3-Year RORE % or its related term are showing as below:
PBIO's 3-Year RORE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -3.95 * Ranked among companies with meaningful 3-Year RORE % only.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Pressure BioSciences 3-Year RORE % Related Terms
Pressure BioSciences 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Pressure BioSciences's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBIO vs EMED, CUTRQ, MHTX: 3-Year RORE % Comparison
For the Medical Devices subindustry, Pressure BioSciences's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pressure BioSciences 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pressure BioSciences's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Pressure BioSciences's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2024 and 3-year before.
Pressure BioSciences (PBIO) has a 3-Year RORE % of 0.00 as of Jun. 2024. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Pressure BioSciences and its competitors.
Is Pressure BioSciences' 3-Year RORE % too high?
Pressure BioSciences' current 3-Year RORE % is 0.00. Overall, Pressure BioSciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Pressure BioSciences' 3-Year RORE % compare to EMED and CUTRQ?
Pressure BioSciences' 3-Year RORE % of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Pressure BioSciences and its competitors. Pressure BioSciences's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pressure BioSciences stock overvalued right now?
Pressure BioSciences (PBIO) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. Pressure BioSciences' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Pressure BioSciences (PBIO), the current 3-Year RORE % is 0.00 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pressure BioSciences Inc is engaged in the healthcare division. The firm is a leader in the development & sale of enabling, pressure-based platform solutions for the world-wide life sciences industry. The company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels. The company is also the distributor of the Constant Systems (CS) cell disruption equipment, parts, and consumables. Its products include Barocyclers, External Pressure Calibration Device Kits, MicroTubes, HUB High-Pressure Generators, and Accessories.
12GF Score
Get the complete analysis for PBIO
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBIO has been successfully added to your 
